Crestline Management, L.P.

FORT WORTH, TX · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$29.3M2026 Q3
Positions2
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

Crestline Management, L.P. reported 2 positions worth $29.3M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: DNLI (92.5%). Biggest move: reduce DNLI ($12.4M).

2 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 DNLIDenali Therapeutics$27.1M92.48%1,310,732——-12.5%
▸ 2 SANASana Biotechnology$2.2M7.52%755,736——-35.5%

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Crestline Management, L.P. hold as of Q3 2026?

Crestline Management, L.P. reported 2 positions worth $29.3M in its Q3 2026 13F filing. Largest positions: DNLI (92.5%) and SANA (7.5%).

What did Crestline Management, L.P. buy in Q3 2026?

Crestline Management, L.P. opened or added to no positions in Q3 2026.

What did Crestline Management, L.P. sell in Q3 2026?

Reduced: DNLI. Sold out entirely: EGHT.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.